PL444442A1 - Amorficzna kompozycja zawierająca kannabidiol oraz melatoninę oraz sposób jej otrzymywania - Google Patents

Amorficzna kompozycja zawierająca kannabidiol oraz melatoninę oraz sposób jej otrzymywania

Info

Publication number
PL444442A1
PL444442A1 PL444442A PL44444223A PL444442A1 PL 444442 A1 PL444442 A1 PL 444442A1 PL 444442 A PL444442 A PL 444442A PL 44444223 A PL44444223 A PL 44444223A PL 444442 A1 PL444442 A1 PL 444442A1
Authority
PL
Poland
Prior art keywords
melatonin
obtaining
composition containing
containing cannabidiol
amorphous composition
Prior art date
Application number
PL444442A
Other languages
English (en)
Other versions
PL247269B1 (pl
Inventor
Justyna Knapik Kowalczuk
Marian Paluch
Martyna Kubajczyk
Original Assignee
Amorphis Pharma Development Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorphis Pharma Development Spółka Z Ograniczoną Odpowiedzialnością filed Critical Amorphis Pharma Development Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL444442A priority Critical patent/PL247269B1/pl
Publication of PL444442A1 publication Critical patent/PL444442A1/pl
Publication of PL247269B1 publication Critical patent/PL247269B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest jednorodna oraz wysoce fizycznie stabilna, zarówno w szkle jak i cieczy przechłodzonej, amorficzna kompozycja farmaceutyczna zawierająca kannabidiol i melatoninę oraz sposób jej otrzymywania.
PL444442A 2023-04-17 2023-04-17 Amorficzna kompozycja zawierająca kannabidiol oraz melatoninę oraz sposób jej otrzymywania PL247269B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL444442A PL247269B1 (pl) 2023-04-17 2023-04-17 Amorficzna kompozycja zawierająca kannabidiol oraz melatoninę oraz sposób jej otrzymywania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444442A PL247269B1 (pl) 2023-04-17 2023-04-17 Amorficzna kompozycja zawierająca kannabidiol oraz melatoninę oraz sposób jej otrzymywania

Publications (2)

Publication Number Publication Date
PL444442A1 true PL444442A1 (pl) 2024-10-21
PL247269B1 PL247269B1 (pl) 2025-06-09

Family

ID=93155103

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444442A PL247269B1 (pl) 2023-04-17 2023-04-17 Amorficzna kompozycja zawierająca kannabidiol oraz melatoninę oraz sposób jej otrzymywania

Country Status (1)

Country Link
PL (1) PL247269B1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858656B2 (en) * 2000-05-17 2010-12-28 Ambros Pharma S.R.L. Controlled release formulations containing an active ingredient, preferably melatonin and the method of preparation
US20180263913A1 (en) * 2017-03-16 2018-09-20 CannTab Therapeutics, Limited Modified Release Multi-Layer Tablet Cannabinoid Formulations
WO2020234675A1 (en) * 2019-04-30 2020-11-26 Vialpando, Llc Amorphous cannabinoid composition and processes of manufacture
US20210137877A1 (en) * 2019-11-07 2021-05-13 Timothy Dale Hewett Products and methods for using cannabidiol in combination with melatonin to induce sleep

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858656B2 (en) * 2000-05-17 2010-12-28 Ambros Pharma S.R.L. Controlled release formulations containing an active ingredient, preferably melatonin and the method of preparation
US20180263913A1 (en) * 2017-03-16 2018-09-20 CannTab Therapeutics, Limited Modified Release Multi-Layer Tablet Cannabinoid Formulations
WO2020234675A1 (en) * 2019-04-30 2020-11-26 Vialpando, Llc Amorphous cannabinoid composition and processes of manufacture
US20210137877A1 (en) * 2019-11-07 2021-05-13 Timothy Dale Hewett Products and methods for using cannabidiol in combination with melatonin to induce sleep

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
N. KOCH ET AL.: "Int. J. Pharm. 2020, 589: 119812", CANNABIDIOL AQUEOUS SOLUBILITY ENHANCEMENT: COMPARISON OF THREE AMORPHOUS FORMULATIONS STRATEGIES USING DIFFERENT TYPE OF POLYMERS. *
O. JENNOTTE ET AL.: "J Drug Deliv Sci Technol. 2022, 71: 103372", DEVELOPMENT OF AMORPHOUS SOLID DISPERSIONS OF CANNABIDIOL: INFLUENCE OF THE CARRIER, THE HOT-MELT EXTRUSION PARAMETERS AND THE USE OF A CRYSTALLIZATION INHIBITOR. *

Also Published As

Publication number Publication date
PL247269B1 (pl) 2025-06-09

Similar Documents

Publication Publication Date Title
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
CL2022001111A1 (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
NO20061906L (no) Terapeutisk middel for mesoteliom
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
MX359882B (es) Amidas como moduladores de canales de sodio.
NO20054359L (no) Cykliske protein tyrosin kinase inhibitorer
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
SV2006002174A (es) Composicion de anticuerpo her2
CL2023000655A1 (es) Degradadores de helios basados en pequeñas moléculas de piperidinilo; y uso
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
PA8595001A1 (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
HN2005036256A (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
CL2025003071A1 (es) Formas cristalinas de inhibidores de ras, composiciones que las contienen y su uso.
UY40235A (es) Compuestos de heteroarilo para el tratamiento del dolor
EA200801997A1 (ru) Новые соединения
UY27983A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
EA200700312A1 (ru) Композиции для доставки лекарственных средств с высокой водорастворимостью
MX2022013081A (es) Compuestos para el tratamiento de sars.
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias